Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

5.89
-0.2800-4.54%
Post-market: 5.890.00000.00%19:37 EDT
Volume:1.45M
Turnover:8.57M
Market Cap:475.65M
PE:-2.92
High:6.16
Open:6.08
Low:5.82
Close:6.17
Loading ...

BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Apr

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Apr

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Apr

Press Release: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
04 Apr

Kura Oncology Announces Preclinical Data for Ko-2806 Selected for Oral Presentation at the 2025 Aacr Annual Meeting

THOMSON REUTERS
·
26 Mar

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

GlobeNewswire
·
26 Mar

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
07 Mar

Kura Oncology Is Maintained at Buy by UBS

Dow Jones
·
07 Mar

UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating

MT Newswires Live
·
06 Mar

Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)

TIPRANKS
·
03 Mar

Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns

TIPRANKS
·
02 Mar

Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago

Simply Wall St.
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Kura Oncology (KURA) and Silence Therapeutics (SLN)

TIPRANKS
·
28 Feb

Q4 2024 Kura Oncology Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Feb

Bullish Outlook for Kura Oncology: Buy Rating Affirmed Amid Optimism for Ziftomenib Approval and Competitive Advantage

TIPRANKS
·
27 Feb

Kura Oncology’s Promising Pipeline and Strategic Focus Justify Buy Rating

TIPRANKS
·
27 Feb

Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth

GuruFocus.com
·
27 Feb

Kura Oncology’s Promising Path to FDA Approval: Analyst Recommends ‘Buy’ Following Positive Phase II Results and Strategic Advancements

TIPRANKS
·
27 Feb

Kura Oncology’s Strategic Advancements and Financial Health Drive Buy Rating

TIPRANKS
·
27 Feb

Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Feb